



HAL
open science

PTPN11 mutations in canine and human disseminated histiocytic sarcoma

Benoit Hedan, Mélanie Rault, Jérôme Abadie, Ronan Ulvé, Nadine Botherel, Patrick Devauchelle, Christiane Copie-Bergman, Edouard Cadieu, Marie Parrens, Julia Alten, et al.

► **To cite this version:**

Benoit Hedan, Mélanie Rault, Jérôme Abadie, Ronan Ulvé, Nadine Botherel, et al.. PTPN11 mutations in canine and human disseminated histiocytic sarcoma. *International Journal of Cancer*, 2020, 147 (6), pp.1657-1665. 10.1002/ijc.32991 . hal-02534873

HAL Id: hal-02534873

<https://univ-rennes.hal.science/hal-02534873v1>

Submitted on 27 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

***PTPN11 mutations in canine and human disseminated
histiocytic sarcoma***

Benoit Hédan^{1*}, Mélanie Rault^{1*}, Jérôme Abadie², Ronan Ulvé¹, Nadine Bothere¹, Patrick Devauchelle³, Christiane Copie-Bergman^{4,5}, Edouard Cadieu¹, Marie Parrens⁶, Julia Alten⁷, Emmanuelle Lechapt Zalcman⁸, Gunnar Cario⁷, Gandhi Damaj⁹, Karima Mokhtari¹⁰, Francois Le Loarer¹¹, Aurore Coulomb-Lhermine¹², Thomas Derrien¹, Christophe Hitte¹, Laura Bachelot¹, Matthew Breen¹³, David Gilot¹, Jean Yves Blay¹¹, Jean Donadieu¹⁴ and Catherine André¹

¹CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, Faculty of Medicine, SFR Biosit, Rennes, France.

²Oniris, Laboniris - Department of Biology, Pathology and Food Sciences, Nantes, France.

³Micen Vet –Créteil, France.

⁴Assistance Publique-Hôpitaux de Paris, Département de Pathologie, Groupe Henri-Mondor Albert-Chenevier, Créteil F-94010, France.

⁵INSERM U955, équipe 9, Faculté de Médecine, Université Paris Est Créteil, Créteil F-94010, France.

⁶Department of Pathology, CHU de Bordeaux, Hôpital du Haut Lévêque, Avenue Magellan, 33604 Pessac, INSERM U1035, Université de Bordeaux, France.

⁷Pediatric Oncology/Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str.3, 24105 Kiel, Germany.

⁸GHU Paris Psychiatrie Neurosciences, Sainte-Anne Hospital, Department of Neuropathology, 75014 Paris, France.

⁹Haemalology Institute, CHU de Caen and Centre François Baclesse, Caen, France.

¹⁰Sorbonne University, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie-Escourolle, Paris, France.

¹¹Department of Medical Oncology, Centre Léon Bérard, Lyon, France.

¹² Department of Pathology, Trousseau Hospital, Paris, France

¹³ Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, CVM Research Building, 1060 William Moore Drive, Raleigh, NC 27607, USA.

¹⁴ Department of Haematology, APHP, Trousseau Hospital, Paris, France.

* Benoit Hédan and Mélanie Rault should be considered joint first authors.

Novelty and Impact :

Due to its rarity, histiocytic sarcoma (HS) is not well known and treatment remains a challenge. Using the canine spontaneous model, we highlighted the association of *PTPN11* somatic mutations to a disseminated subtype of HS in humans and dogs. Thanks to in-house canine HS cell lines, we tested MAP kinase inhibitors as a proof of concept of the interest of this model for the development and selection of efficient therapies.

List of abbreviations

HS: Histiocytic Sarcoma

MH: Malignant Histiocytosis

BMD: Bernese Mountain Dogs

LOH: Loss Of Heterozygosity

ctDNA: cell free circulating tumor DNA

Abstract

In humans, histiocytic sarcoma (HS) is an aggressive cancer involving histiocytes. Its rarity and heterogeneity explain that treatment remains a challenge. Sharing high clinical and histopathological similarities with human HS, the canine HS is conversely frequent in specific breeds and thus constitutes a unique spontaneous model for human HS to decipher the genetic bases and to explore therapeutic options. We identified sequence alterations in the MAPK pathway in at least 63.9% (71/111) of HS cases with mutually exclusive *BRAF* (0.9%; 1/111), *KRAS* (7.2%; 8/111) and *PTPN11* (56.75%; 63/111) mutations concentrated at hotspots common to human cancers. Recurrent

PTPN11 mutations are associated to visceral disseminated HS subtype in dogs, the most aggressive clinical presentation. We then identified *PTPN11* mutations in 3/19 (15.7%) human HS patients. Thus, we propose *PTPN11* mutations as key events for a specific subset of human and canine HS: the visceral disseminated form. Finally, by testing drugs targeting the MAPK pathway in eight canine HS cell lines, we identified a better anti-proliferation activity of MEK inhibitors than *PTPN11* inhibitors in canine HS neoplastic cells. In combination, these results illustrate the relevance of naturally affected dogs in deciphering genetic mechanisms and selecting efficient targeted therapies for such rare and aggressive cancers in humans.

Introduction

Histiocytic sarcomas (HS), also referred as Malignant Histiocytosis (MH), are rare tumors characterized by proliferation of cells with the phenotype of mature tissue histiocytes¹. Half of the cases occur in the context of a previous lymphoid or myeloid neoplasm, while the other half are considered as primitive proliferation of histiocytes¹. This aggressive tumor leads to a high mortality and currently there is neither consensus on prognostic factors, nor on standard treatment. Recent publications showed that the MAPK pathway, with *BRAF* alterations, plays a crucial role in the development of HS²⁻⁶. Drugs targeting this pathway such as vemurafenib or sorafenib have shown clinical responses in HS cases^{7,8}. The rarity and heterogenous nature of this cancer poses significant challenges to advancing knowledge, limiting opportunities to identify recurrent alterations with driver roles and aiding selection of targeted therapies.

Interestingly, this tumor type, occurring naturally and well-characterized in the domestic dog, is especially prevalent (up to 20%) in some popular predisposed breeds, including Bernese mountain dogs (BMD), rottweilers and retrievers⁹⁻¹¹. Genetic predispositions in these breeds have led to the availability of many naturally affected cases with homogeneous clinical presentation in a specific canine breed^{9,10}. Indeed, BMDs more frequently display disseminated HS with simultaneous involvement of

multiple internal organs at time of diagnosis, whereas retrievers more often develop localized HS with tumor initially restricted to joint, muscle or subcutaneous tissue. Using this unique resource to characterize HS, we identified recurrent gain-of-function mutations in the MAPK pathway in canine and then in human HS. The *PTPN11* mutations - the main recurrent alterations in canine HS (56.75%; 63/111)- are associated with the visceral disseminated canine HS subtype. We thus proposed that *PTPN11* mutations are also characteristic of a visceral disseminated form of human HS. By developing seven canine HS in-house cell lines, we tested drugs targeting directly *PTPN11* or the MAPK pathway and confirmed the antitumor activity of MEK inhibitors in canine HS neoplastic cells, illustrating the potential of the dog model to screen drugs to improve therapies of this rare and aggressive cancer.

Material & Method

Sample collection

Blood and tissue biopsy samples from dogs were collected by veterinarians through the Cani-DNA BRC (<http://dog-genetics.genouest.org>) and DNA/RNA was extracted as previously described¹². Blood was also collected on Cell-free DNA BCT (Streck, La Vista, Nebraska, USA) and cell-free circulating DNA was extracted with NucleoSnap® DNA Plasma (Macherey Nagel, Düren, Germany) according to the manufacturer protocol. The canine HS cases were diagnosed by histopathological analysis (JA) with adequate immunostaining (CD204 SRA-E5 Abcam MAB1710).

Seventeen human DNA samples were collected through the French Histiocytosis Registry, approved by the Comité de Protection des Personnes Ile de France III (#2011-A00447-34) over a fifteen-year period (2003-2018). Diagnosis of primary HS was established according to the classification of histiocytosis¹ and cases were independently reviewed by experienced human pathologists. DNA was extracted either from FFPE tissues or from snap frozen tissue biopsies samples, part of them by the Department of Pathology (APHP University Hospital Ambroise Paré, Boulogne, France) thanks to Jean-Francois Emile. Two additional cases were obtained from the literature¹³(Table 1).

Sequencing

RNA-Seq and Sanger sequencing were performed on canine samples as previously described¹². For all mutations, their somatic status was assessed with the corresponding constitutional DNAs. Human DNA libraries for *PTPN11* sequencing were prepared by targeted enrichment and amplicon tagging (Access array barcode - Fluidigm, San Francisco, USA). When high quality and quantity DNA samples were available, *BRAF* and *KRAS* hot spots were also amplified. The libraries were sequenced by MiSeq following

Accepted Article
Illumina's protocol (sequencing platform GEH, Biosit, Rennes). Primers are available in Supplementary Table 1.

Cell lines

The 8 cell lines include one commercial cell line (DH82 (ATCC CRL-10389; RRID:CVCL_2018) and seven cell lines developed in the team from HS affected dog fresh tissues (supplementary table 2). These seven cell lines are available on request. Cells were cultivated in a complete RPMI medium containing RPMI 1640 GlutaMAX supplemented medium (Gibco. life technologies) with 10% of Fetal Bovine Serum (HyClone, GE Healthcare, Life ScienceS, Logan, USA) and 0,025% of Primocin (InvivoGen, Toulouse France) at 37 °C in a humidified 5% CO₂ incubator. All cell lines were tested for mycoplasma with MycoAlert™ Plus kit (Lonza; Rockland; ME; USA) and were mycoplasma-free cells.

Drug tests on canine HS cell lines

We tested four drugs targeting the MAPK pathway: U0126 (Promega Co., Madison, USA), GS-493, kindly provided by Dr Birchmeier and Dr Land, Sorafenib (Santa Cruz Biotechnology Inc., Dallas, USA) and Trametinib (Active Biochemicals Co., Hong Kong). Stock solutions of drugs were made in DMSO. The cells were cultured for 24h in 96-well plates and the drug or the DMSO alone was then added for additional 72H. Six biological replicates were used for each drug concentration tested, and 12 replicates for the DMSO controls. Cell proliferation was evaluated by methylene blue assays. A Dixon test was performed for each replicate and the proliferation rate was normalized with the DMSO control for each cell line. IC₂₅s were fitted by non-linear regression (Weibull equation, maximum 1, minimum estimated) using the GraphPad Prism version 6.00 (GraphPad Software, La Jolla California USA).

Statistical analyses

Statistical analyses were performed using the R software (Vienna, Austria). Fisher's Exact tests were used to evaluate the association between *PTPN11* mutations and clinical parameters, Wilcoxon Mann Whitney test was used to compare IC25 distribution between homozygous and heterozygous *PTPN11* mutated cell lines. Values of $p < 0.05$ were considered statistically significant.

Data availability

RNA-seq data are available at European Nucleotide Archive (accession number: PRJEB36828). Other data will be made available upon reasonable request.

Material & Method for the primer design, the Western-blot, the Cytogenetic and LOH analyses are available in Supplementary Material & Method.

Results

To characterize somatic alterations in histiocytic sarcomas, we performed RNA-Seq on three canine HS cases and the commercial cell line DH82 and we identified two somatic mutations in *PTPN11*. These two mutations are homologous to the human *PTPN11* E76K and G503V mutations occurring in hotspot regions of this gene in human cancers (COSMIC database)¹⁴. To estimate the frequency and analyze the relevance of *PTPN11* mutations, and more widely of the MAPK pathway involvement in HS oncogenic events, we searched for the presence and recurrence of somatic mutations in *PTPN11*, *KRAS*, *NRAS*, *HRAS*, *BRAF* and *CBL* in all 111 canine HS cases. All tumors except one were found wild-type for *BRAF*. This *BRAF*-mutated case presented two mutations orthologous to human S465T and G469A *BRAF* mutations. We found *PTPN11* and *KRAS* somatic mutations in 56,7% (63/111) and 7.2% (8/111) of cases respectively, indicating alterations of the MAPK pathway in 63.9% of canine HS (Figure 1 and Supplementary Table 2). These mutations were mutually exclusive in all but one case, a composite heterozygous case. We found that *PTPN11* mutations were enriched, but not significantly, in the BMD breed (58.8% vs 47.6% p-value=0.46, Fisher's Exact test), in

agreement with the recent identification of the *PTPN11* mutations in canine HS associated with BMD¹⁵. In our large canine cohort, we identified an association between *PTPN11* somatic mutations and the internal localization of tumors or HS disseminated forms (p-value=1.27x10⁻⁴, and p-value=1.6x10⁻⁶ respectively, Fisher's Exact test). These results indicate that *PTPN11* mutations are associated with the aggressive form of disseminated HS rather than the localized HS forms in dogs.

These mutations in the *PTPN11* protein in canine HS are distributed at two hotspots, identical to those observed in human cancers (Figure 1 B) and inducing over-activation of PTPN11 in juvenile myelo-monocytic leukemia¹⁶. As expected with the strong sequence identity (99%) between the human and canine *PTPN11* proteins, these gain-of-function mutations in dogs are also associated with MAPK pathway activation¹⁵. By Western Blot analyses, we confirmed the constitutive activation of the MAPK pathway (pERK) in 2 HS cell lines harboring *PTPN11* mutations (Supplementary Figure 1).

Moreover, with the high incidence of this tumor in dogs, this natural model allows to study the life history of HS and the timing of *PTPN11* mutations in disseminated HS. Using CGH and Loss of Heterozygosity (LOH) analyses of 13 tumor samples from five dogs presenting with several histiocytic masses, we showed that 4/5 cases had a common origin with a clonal linear evolution, demonstrating the metastatic origin of disseminated HS (Figure 2, Supplementary Figure 2). For the one case presenting different CGH profiles between lung tumor and spleen/lymph node tumors, the LOH analysis is in favor of a common origin of disseminated HS ($P_{\text{chromosome}} = 0.0058$ and $P_{\text{marker}} = 0.0022$) with subsequent genetic divergence (Supplementary Table 4). This case suggests that *PTPN11* mutations probably occur in late stages of the tumor.

Considering the high frequency of the *PTPN11* gain-of-function mutations in disseminated canine HS, we hypothesize that *PTPN11* mutations can also be a key event in a subset of human HS. We then explored the frequency of *PTPN11* mutations in 19

human MH cases with visceral masses. Using high throughput sequencing, we identified *PTPN11* mutations in three cases (Table 1). Interestingly, the recent report of Shanmugman et al. (2019), identifying two *PTPN11* mutations in two patients with internal and multifocal tumors, confirmed that *PTPN11* mutations are enriched in visceral disseminated cases (p-value = 0.0476 one sided Fisher's Exact Test)⁵. Moreover, Egan et al. (2019) recently showed the existence of a distinct subtype of primary HS characterized by *PTPN11* alterations enriched in gastrointestinal tract localizations¹⁷. Altogether, these results strongly suggest that *PTPN11* mutations drive the growth of histiocytic neoplasms in humans as in dogs. Moreover, the canine data highlight that the key *PTPN11* mutations are associated with visceral dissemination and aggressiveness of HS. For four samples with enough available DNA, we also explored *BRAF* and *KRAS* hotspots, previously found exclusively mutated with *PTPN11* in canine HS. Interestingly, in WT-*PTPN11* human patients, we identified two *KRAS* mutations (G12D and Q61H) and one *BRAF* mutation (G464V) (Table 1). While the number of cases is limited, our results and the literature confirmed our hypotheses that *PTPN11* mutations, as *BRAF* and *KRAS* mutations are a key mechanism of the MAPK pathway activation, playing a crucial role in the physiopathology of HS in humans and dogs.

The identification of driver events is a key step in proposing targeted therapies, as shown by Diamond *et al.* who demonstrated the clinical efficacy of MEK and RAF inhibitors on *MAP2K1*- and *ARAF*-mutated Histiocytic Neoplasms⁷. We thus proposed the spontaneous disseminated form of canine HS as a relevant model to evaluate candidate drugs for treating human *PTPN11*-mutated HS patients. Thus, we developed seven canine in-house HS cell lines. These cell lines as well as the commercial cell line DH82 were all mutated for *PTPN11* (homozygous or heterozygous state); one cell line was also heterozygous for the *KRAS* Q61H mutation (Supplementary Table 3). We studied their sensitivity, together with the DH82 cell line, to three drugs targeting the MAPK pathway. Based on the development of personalized medicine and interest of targeting *PTPN11* in human cancers¹⁸, we tested a *PTPN11* inhibitor, GS-493, expected

to inhibit the phosphatase activity in PTPN11 gain of function mutant¹⁹. We compared it with Trametinib and Sorafenib, two FDA-approved drugs with clinical efficacy in human histiocytic neoplasms⁷. The three inhibitors decreased the cell density for all cell lines (Figure 3). Homozygous or compound heterozygous *PTPN11* mutated cell lines were more sensitive to the PTPN11 inhibitor GS-493 than heterozygous cell lines (p-value= 0.02857 One Sided Wilcoxon Mann Whitney test). However, the highest sensitivity to inhibitors was observed with Trametinib (IC₂₅ = 3,01.10⁻³ μM; ±5,10.10⁻³ μM) (Supplementary Table 5).

Based on the *PTPN11* and *KRAS* mutations detected in the *BRAF* wild type canine HS, we confirmed that targeting the RAF/RAS/MEK pathway with MEK inhibitors such as Trametinib is a promising therapeutic option for patients with histiocytic sarcoma especially disseminated cases, harboring *PTPN11* mutations. These results emphasize the relevance of the canine spontaneous model for the selection of more efficient therapies.

Discussion

Comparative oncology across species appears useful to identify driver molecular alterations in similar nosological entities, and may guide research for both species, which could prove extremely useful for rare human cancers. The present complementary approach is based on large cohorts and identifies *PTPN11* mutations both in frequent canine and rare human aggressive histiocytic sarcoma. Our results demonstrated the association of *PTPN11* mutations with disseminated canine HS, the most aggressive subtype, and highlighted that human patients harboring *PTPN11* mutations also share a similar disseminated clinical presentation. Our results expand the current understanding of the pathogenesis of histiocytic neoplasms and offer new opportunities for the comprehension of the genetic mechanisms. They also provide clues to new therapeutic approaches for the mutual benefit of human and veterinary medicine. Last, this approach, using naturally affected dogs, in a non-experimental

frame, is respectful of the ethics and of the 3R rule, by replacing experimental animals by pet dogs in the frame of their health care.

Through a unique series of 111 canine HS cases, we showed the high prevalence of *PTPN11* mutations at the two key hot spots (56.75%) and that these alterations are linked to an aggressive HS subtype. This work confirmed the recent identification of *PTPN11* mutations in canine HS associated to the BMD breed¹⁵. In our cohort, we detected a more significant association with the visceral disseminated HS forms than with the breed, due to the fact that BMD is mainly affected by disseminated HS form¹⁰. The link between *PTPN11* mutations and an aggressive clinical presentation of this histiocytic neoplasm is supported by the identification of three *PTPN11* mutations in human cases with internal tumors as well as cases from the literature: except for one case with “unspecified lymph node” localization, all published human cases to date (10 cases), with *PTPN11* somatic alterations presented internal masses, including kidney, spleen or brain localizations^{4,5,17,20–22}. Moreover the mutated patients presented multifocal masses with dramatic evolution similar to canine disseminated HS^{4,5,20–22}. Finally, the recent work of Egan *et al.* clearly showed that human HS cases with *PTPN11* alterations form a distinct subtype of primary HS with predilection to gastrointestinal tract¹⁷, these recent results reinforcing our work. Altogether, our data refined our comprehension of the genetic bases of HS in dogs and humans, by associating *PTPN11* mutations to an aggressive clinical presentation associated to internal/visceral masses.

In this study, we also identified mutations exclusive to *PTPN11* in the same hotspots of *KRAS* and *BRAF* in canine and human HS cases, confirming the driving role of these *KRAS* and *BRAF* mutations in histiocytic neoplasms as previously shown^{4,5,17,20–23}. Noticeably, the *BRAF* mutations identified in canine and human HS cases were found in the GSGSFG phosphate binding loop (P-loop) at residues 464–469 and constitute novel relevant mutations since this region, with the V600 region, contain the majority of *BRAF* mutations in human cancers²⁴.

The attractiveness of the spontaneous canine model, is based on the higher HS frequency due to a strong breed predisposition^{10,11} and clinical homogeneity, recapitulating the clinical presentations of primary human HS. This model thus offers a great potential to decipher the genetic mechanisms involved in rare human clinical subtypes and also to screen for targeted therapies. Previous studies orientated treatments towards MEK inhibition in canine and in human HS^{7,20,25,26}. In the context of *PTPN11* alterations, we tested a specific *PTPN11* inhibitor, which surprisingly was, *in vitro*, less efficient than MEK inhibitors. Interestingly, one cell line (Dog-HS-13281) is clearly more sensitive to the tested inhibitors probably due to the presence of *KRAS* complementary mutation (Supplementary table 4). Future studies are needed to explore the targeted therapies, especially in case of partial²⁰ or refractory responses⁸. The mechanisms of resistance, only explored to date in one patient⁵, are expected especially if the MAPK pathway activation with *PTPN11* mutations occurs at a late stage of tumoral development as suggested by our results. We hypothesize that this late event leads to HS dissemination but further studies are needed to exclude that *PTPN11* mutated HS could represent a different nosological entity with a specific origin of histiocytes than *PTPN11* wild-type HS. Last, we succeeded in detecting *PTPN11* mutations in cell free circulating tumor DNA (ctDNA) of canine cases (Supplementary Table 2). Thus the spontaneous canine HS model, with the availability of numerous cases and the possibility of therapeutic response follow-up with the ctDNA is a unique opportunity to explore therapeutic options and resistance mechanisms through *in vitro* screening in canine HS cell lines and *in vivo* pre-clinical trials in pet dogs.

In conclusion, through access to a large cohort of canine HS, we identified MAPK pathway-activating *PTPN11* mutations, which point out a specific aggressive disseminated HS subgroup in dogs and in humans. We propose that the key *PTPN11* mutations occur in late stage of tumorigenesis with tumoral dissemination. Our findings strongly advocate the rationale for MAPK inhibition in *BRAF*-wild-type HS cases and we propose to take advantage of the unique resource of canine cases to screen inhibitor

efficiency as has already been done in integrated approaches with pet dogs clinical trials²⁷. Finally, this work confirms the value of naturally occurring canine cancers as models for the study of rare human cancers from the discovery of mutations to the development and the screening of targeted therapies.

Acknowledgments

We thank Olivier Albaric and Laetitia Dorso (Laboniris, Oniris, Ecole Nationale Vétérinaire de Nantes, France) as well as Marie-Odile SEMIN (LAPV, Amboise, France), Caroline Laprie (Vet-Histo, Marseille, France), Marie Lagadic (Idexx Alfort, France), Frédérique Degorce-Rubiale (LAPVSO, Toulouse, France) who provided veterinarian anatomopathologic diagnoses. We thank the veterinarians for providing us with clinical data and samples, as well as dog owners, breeders and breed clubs, especially the French club AFBS, European clubs, the American club BMDCA, the IWG International Working Group (for Bernese Mountain Dogs) and the US Berner garde foundation, especially Pat Long for her dedicated trust and follow-up of our work.

We also warmly thank Dr Frédéric Charlotte (CHU Pitié-Salpêtrière, Paris, France), Pr Nicole Brousse (Necker Hospital, Paris, France), Dr Claire Danel (Bichat Hospital, Paris, France), Dr Virginie Verkarre and Dr Sylvie Fraitag (Necker Hospital, Paris, France), Dr Anne Moreau (Nantes Hospital, France) and Dr Catherine Chassagne-Clement (Unicancer, Lyon, France) who provided human anatomopathologic diagnoses. We warmly thank Wouters Coppieters, Anne-Sophie Lequarré and Michel Georges (GIGA-Genomics, Université de Liège, Belgique) for RNA-Seq facilities, Stéphane Dréano (IGDR, Rennes, France) for Sanger sequencing and the Biogenouest bioinformatic platform. We warmly thank the Reference Center for Histiocytoses, France who kindly provided FFPE samples of patients. We warmly thank Dr W. Birchmeier and Dr L. Land (Max Delbrueck Center for Molecular Medicine, Berlin, Allemagne) who kindly provided GS-493. We

thank Alexandra Lespagnol (CHU Rennes, France), for scientific advices on circulating DNAs.

Supports

This study was supported by CNRS and INCa PLBio “canine rare tumours” funding (N° 2012-103; 2012-2016), in the frame of the Plan Cancer 2009-2013 , by the CRB-Anim infrastructure ANR-11-INBS-0003 and in the frame of the ‘Investing for the Future Program (PIA) for the Cani-DNA BRC and by AKC CHF funding (N°1557, 2446 and 2667). Mélanie Rault, PhD was funded through a French “Ministère de la recherche” funding (2013-2016).

Author’s Contributions

Conception and design: B. Hedan, M.Rault, J. Donadieu, C. André

Development of methodology: B. Hedan, M. Rault, R. Ulve, E. Cadieu

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): B. Hedan, M. Rault, R. Ulve, J. Abadie, N. Botherel, L. Bachelot, D. Gilot, J. Donadieu, K. Mokhtari, MC.Parrens, G. Damaj, C. Copie, E. Lechapt Zalcman, F. Le Loarer, M. Breen, P. Devauchelle, G. Cario, J. Alten. A. Coulomb-Lhermine.

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B. Hédan, M. Rault, C. Hitte, T. Derrien, C. André

Writing, review, and/or revision of the manuscript: B. Hedan, M. Rault, C. André, J. Donadieu, D. Gilot, JY. Blay, M. Breen.

Disclosure of Conflicts of Interest

No conflicts of interest

References

1. Emile J-F, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. *Blood* 2016;127:2672–81.
2. Go H, Jeon YK, Huh J, Choi SJ, Choi Y-D, Cha HJ, Kim H-J, Park G, Min S, Kim JE. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. *Histopathology* 2014;65:261–72.
3. Kordes M, Roring M, Heining C, Braun S, Hutter B, Richter D, Georg C, Scholl C, Groschel S, Roth W, Rosenwald A, Geissinger E, et al. Cooperation of BRAF and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. *Leukemia* 2015;
4. Liu Q, Tomaszewicz K, Hutchinson L, Hornick JL, Woda B, Yu H. Somatic mutations in histiocytic sarcoma identified by next generation sequencing. *Virchows Arch Int J Pathol* 2016;
5. Shanmugam V, Griffin GK, Jacobsen ED, Fletcher CDM, Sholl LM, Hornick JL. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. *Mod Pathol Off J U S Can Acad Pathol Inc* 2019;
6. Michonneau D, Kaltenbach S, Derriex C, Trinquand A, Brouzes C, Gibault L, North M-O, Delarue R, Varet B, Emile J-F, Brousse N, Hermine O. BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia. *J Clin Oncol Off J Am Soc Clin Oncol* 2014;32:e117–21.
7. Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC-W, Gao Y, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. *Cancer Discov* 2016;6:154–65.
8. Idbaih A, Mokhtari K, Emile J-F, Galanaud D, Belaid H, de Bernard S, Benameur N, Barlog V-C, Psimaras D, Donadieu J, Carpentier C, Martin-Duverneuil N, et al. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. *Neurology* 2014;83:1478–80.
9. Abadie J, Hedan B, Cadieu E, De Brito C, Devauchelle P, Bourgain C, Parker HG, Vaysse A, Margaritte-Jeannin P, Galibert F, Ostrander EA, Andre C. Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed. *J Hered* 2009;100 Suppl 1:S19–27.
10. Hedan B, Thomas R, Motsinger-Reif A, Abadie J, Andre C, Cullen J, Breen M. Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior. *BMC Cancer* 2011;11:201.
11. Shearin AL, Hedan B, Cadieu E, Erich SA, Schmidt EV, Faden DL, Cullen J, Abadie J, Kwon EM, Grone A, Devauchelle P, Rimbault M, et al. The MTAP-CDKN2A locus confers susceptibility to a naturally occurring canine cancer. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol* 2012;21:1019–27.
12. Ulve R, Rault M, Bahin M, Lagoutte L, Abadie J, De Brito C, Coindre J-M, Botharel N, Rousseau A, Wucher V, Cadieu E, Thieblemont C, et al. Discovery of human-similar gene

fusions in canine cancers. *Cancer Res* 2017;

13. Alten J, Klapper W, Leuschner I, Eckert C, Beier R, Vallo E, Krause M, Claviez A, Vieth S, Bleckmann K, Moricke A, Schrappe M, et al. Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer* 2015;62:1656–60.
14. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. *Br J Cancer* 2004;91:355–8.
15. Takada M, Smyth LA, Thaiwong T, Richter M, Corner SM, Schall PZ, Kiupel M, Yuzbasiyan-Gurkan V. Activating Mutations in PTPN11 and KRAS in Canine Histiocytic Sarcomas. *Genes* 2019;10.
16. Rehman AU, Rahman MU, Khan MT, Saud S, Liu H, Song D, Sultana P, Wadood A, Chen H-F. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer. *Curr Pharm Des* 2018;24:3767–77.
17. Egan C, Nicolae A, Lack J, Chung H-J, Skarshaug S, Pham TA, Navarro W, Abdullaev Z, Aguilera NS, Xi L, Pack S, Pittaluga S, et al. Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. *Haematologica* 2019;
18. Prahallad A, Heynen GJJE, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Bernards R. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. *Cell Rep* 2015;12:1978–85.
19. Grosskopf S, Eckert C, Arkona C, Radetzki S, Bohm K, Heinemann U, Wolber G, von Kries J-P, Birchmeier W, Rademann J. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. *ChemMedChem* 2015;10:815–26.
20. Voruz S, Cairoli A, Naveiras O, de Leval L, Missiaglia E, Homicsko K, Michielin O, Blum S. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. *Haematologica* 2018;103:e39–41.
21. Batra S, Martin SC, Nassiri M, Qureshi A, Markel TA. Histiocytic Sarcoma Associated with Coombs Negative Acute Hemolytic Anemia: A Rare Presentation. *Case Rep Oncol Med* 2016;2016:3179147.
22. Zhang Q, Shibani A, Sadikovic B, Howlett CJ, Ang L-C. An aggressive multifocal primary CNS histiocytosis with PTPN11 (Shp2) mutation. *Neuropathol Appl Neurobiol* 2018;44:240–3.
23. Goyal G, Lau D, Nagle AM, Vassallo R, Rech KL, Ryu JH, Davidge-Pitts CJ, Tobin WO, Koster MJ, Bennani NN, Shah MV, Liu MC, et al. Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. *Blood* 2019;133:1607–10.
24. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. *Nat Rev Cancer* 2014;14:455–67.
25. Gounder MM, Solit DB, Tap WD. Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. *N Engl J Med* 2018;378:1945–7.
26. Takada M, Hix JML, Corner S, Schall PZ, Kiupel M, Yuzbasiyan-Gurkan V. Targeting MEK in a Translational Model of Histiocytic Sarcoma. *Mol Cancer Ther* 2018;17:2439–50.

27. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. *Nat Rev Cancer* 2008;8:147–56.

Accepted Article



Figure and table legends

Figure 1: MAPK alterations in canine HS. A) Landscape of somatic mutations of several MAPK oncogenes in 111 cases of canine HS. *PTPN11* hotspots are mutated in 56,75% of the 111 cases of canine HS (63/111), *KRAS* hotspots are mutated in 7.2% of the cases (8/111), *BRAF* is mutated in 0.9%, while no mutation is found in *HRAS*, *NRAS* or *CBL* hotspots. B) Distribution of *PTPN11* mutations along the protein sequence in the canine HS cases compared to the *PTPN11* mutations reported for human cancers (COSMIC database).


Figure 2: Hierarchical clustering of disseminated histiocytic sarcomas from five dogs. A) The algorithm summarizes relationships between the genomic aberrations of different tumors detected by CGH data in a dendrogram, in which pattern and length of the branches reflect the relatedness of samples. B) CGH profile of sarcoma cases: larger pictures of CGH profiles are available in supplementary Figure 2. C) *PTPN11* mutations. Mutations detected by Sanger sequencing are indicated by *. The mutations *PTPN11*^{G503V}, *PTPN11*^{E76G} and *PTPN11*^{G60D} were detected in Case 2, Case 3 and Case 5 respectively. The *PTPN11*^{E76G} was detected in the lung of Case 4 while *PTPN11*^{E76K} was detected in the spleen and lymph node tumors of Case 4.


Figure 3: Inhibitory effect of U0126, GS-493, Sorafenib and Trametinib on 72h cell proliferation of eight canine HS cell lines. All the cell lines are sensitive to the four inhibitors, with a higher sensitivity for the Trametinib.

Table 1: Human HS cases Summary. Cases were collected through the Reference Center for Histiocytoses, France and from the literature. Somatic alterations detected by NGS are indicated: mutations of *PTPN11* according to ENST00000351677, mutations of *KRAS* according to ENST00000256078.9, mutations of *BRAF* according to ENST00000496384.7.




Review







— DH82
— Dog-HS-7051
— Dog-HS-10013
— Dog-HS-10237
— Dog-HS-5029
— Dog-HS-5472S
— Dog-HS-5472L
— Dog-HS-13281



— DH82
— Dog-HS-7051
— Dog-HS-10013
— Dog-HS-10237
— Dog-HS-5029
— Dog-HS-5472S
— Dog-HS-5472L
— Dog-HS-13281



— DH82
— Dog-HS-7051
— Dog-HS-10013
— Dog-HS-10237
— Dog-HS-5029
— Dog-HS-5472S
— Dog-HS-5472L
— Dog-HS-13281



— DH82
— Dog-HS-7051
— Dog-HS-10013
— Dog-HS-10237
— Dog-HS-5029
— Dog-HS-5472S
— Dog-HS-5472L
— Dog-HS-13281

Case No.	Age (years)	Sex	Tumor site	Outcome, follow-up	Prior/concurrent hematologic malignancy	mutations in PTPN11	Other Mutations	Previous reference (PMID)	Clonality
1	82	M	bone, orbit	Death 5.14 months		WT	NA	NA	
2	74	M	Lymph Node	Death 8.5 months		WT	NA	NA	
3	1	F	Lymph Node, lung	Death 8.16 months		WT	NA	NA	
4	63	F	liver	Death 13.96 months	CLL	PTPN11:chr12:112450451 A>G(91)	NA	NA	NA
5	25	M	NA	NA	NA	WT	NA	NA	
6	42	F	brain	Death 26.88 months		PTPN11:chr12:112450406 G>A(76)	NA	NA	
7	27	F	brain/spinal corde	Death 3.51 months		WT	NA	NA	
8	NA	F	NA	NA	NA	WT	NA	NA	
9	42	M	Lymph node	Death 60.91 months	LCH	WT	NA	NA	NA
10	61	F	Digestive tract	NA		WT	NA	NA	
11	21	M	Skin, lymph node	Death 14.26 months		WT	NA	NA	
12	74	M	Lymph node, digestive	Death 4.72 months		WT	NA	NA	

			tract							
13	8	M	Lymph Node	Death 24.98 months	pre B ALL	WT		NA	NA	NA
14	78	F	Bone, liver, brain	Death 3.05 months		PTPN11:chr12:112450385 G>A(69)		NA	NA	
15	81	M	Lymph node	Alive 5.5 years		WT		KRAS:chr12:25227341 T>G (61)	NA	
16	66	F	Lymph node, digestive tract, liver	Death 9.3 years		WT		WT	NA	
17	4	F	Lymph node, lung. Spleen, liver	Death 9 days	T ALL	WT		KRAS:chr12:25245350 C>T (12)	NA	NA
18	7	M	BM, liver, spleen, LN	Death 6 weeks	T ALL	WT		KRAS:chr12:25245350 C>T(12) BRAF:chr7:140781617 C>A (464)	25833113	yes
19	12	M	BM, skin, liver, spleen	Death 10 months	T ALL	WT		WT	25833113	yes